UBS Group Lowers Integra Lifesciences (IART) to Market Perform

UBS Group lowered shares of Integra Lifesciences (NASDAQ:IART) to a market perform rating in a research report released on Tuesday, The Fly reports.

Other research analysts also recently issued reports about the company. Jefferies Group reaffirmed a buy rating and set a $56.00 target price on shares of Integra Lifesciences in a report on Sunday, October 29th. Zacks Investment Research raised Integra Lifesciences from a hold rating to a buy rating and set a $55.00 target price on the stock in a report on Tuesday, October 10th. Oppenheimer reaffirmed a buy rating and set a $60.00 target price on shares of Integra Lifesciences in a report on Monday, September 18th. TheStreet downgraded Integra Lifesciences from a b rating to a c+ rating in a report on Thursday, October 26th. Finally, Barclays reaffirmed an equal weight rating and set a $53.00 target price (up from $47.00) on shares of Integra Lifesciences in a report on Tuesday, September 12th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus target price of $53.64.

Integra Lifesciences (IART) traded up $0.08 during midday trading on Tuesday, hitting $47.17. The company had a trading volume of 312,700 shares, compared to its average volume of 502,700. The company has a debt-to-equity ratio of 1.26, a quick ratio of 3.39 and a current ratio of 4.49. Integra Lifesciences has a 12 month low of $40.51 and a 12 month high of $56.42. The firm has a market cap of $3,695.50, a P/E ratio of 77.33, a price-to-earnings-growth ratio of 1.56 and a beta of 0.65.

Integra Lifesciences (NASDAQ:IART) last released its quarterly earnings data on Thursday, October 26th. The life sciences company reported $0.45 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.47 by ($0.02). Integra Lifesciences had a net margin of 4.52% and a return on equity of 16.35%. The firm had revenue of $278.83 million for the quarter, compared to analyst estimates of $286.00 million. During the same period last year, the business earned $0.93 EPS. The company’s revenue was up 11.4% compared to the same quarter last year. equities research analysts anticipate that Integra Lifesciences will post 1.85 EPS for the current year.

In other news, VP Richard D. Gorelick sold 1,500 shares of Integra Lifesciences stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $47.19, for a total value of $70,785.00. Following the completion of the transaction, the vice president now directly owns 21,665 shares of the company’s stock, valued at approximately $1,022,371.35. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Barbara B. Hill acquired 10,768 shares of the stock in a transaction dated Tuesday, October 31st. The stock was acquired at an average cost of $46.66 per share, with a total value of $502,434.88. Following the completion of the transaction, the director now owns 55,540 shares in the company, valued at approximately $2,591,496.40. The disclosure for this purchase can be found here. Company insiders own 21.50% of the company’s stock.

Several hedge funds have recently bought and sold shares of the company. Pinebridge Investments L.P. raised its position in shares of Integra Lifesciences by 2.2% in the 2nd quarter. Pinebridge Investments L.P. now owns 7,971 shares of the life sciences company’s stock worth $435,000 after acquiring an additional 174 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in shares of Integra Lifesciences by 3.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,409 shares of the life sciences company’s stock worth $295,000 after acquiring an additional 187 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Integra Lifesciences by 8.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,752 shares of the life sciences company’s stock worth $150,000 after acquiring an additional 218 shares in the last quarter. Public Employees Retirement System of Ohio raised its position in shares of Integra Lifesciences by 0.5% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 55,635 shares of the life sciences company’s stock worth $3,033,000 after acquiring an additional 300 shares in the last quarter. Finally, Pacer Advisors Inc. raised its position in shares of Integra Lifesciences by 6.4% in the 2nd quarter. Pacer Advisors Inc. now owns 6,236 shares of the life sciences company’s stock worth $340,000 after acquiring an additional 376 shares in the last quarter. 87.58% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/3127147/ubs-group-lowers-integra-lifesciences-iart-to-market-perform.html.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

The Fly

Analyst Recommendations for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.